Developing PBPK Model-Based Mechanistic IVIVCs for Long Acting Injectable Suspensions and
The objective of this research proposal is to develop physiologically based pharmacokinetic (PBPK) model-based mechanistic in vitro in vivo correlations (IVIVCs) for two major types of long acting injectables (LAIs) such as crystalline suspensions and polymer-based implants by considering their distinct characteristics
| Agency | Food and Drug Administration |
|---|---|
| Status | Forecasted |
| Opportunity number | FOR-FD-24-002 |
| Posted date | 11/21/2023 |
| Award ceiling | 300,000 |
| Estimated total funding | 600,000 |
| Expected number of awards | 2 |
| Who can apply | Independent School DistrictsPublic Housing Authorities/Indian Housing AuthoritiesNative American Tribal Organizations (other than Federally recognized tribal governments)Faith-based or Community-based OrganizationsRegional OrganizationsNon-domestic (non-U.S.) Entities (Foreign Institutions |
| Assistance Listing (CFDA) | 93.103 |
| Description | The objective of this research proposal is to develop physiologically based pharmacokinetic (PBPK) model-based mechanistic in vitro in vivo correlations (IVIVCs) for two major types of long acting injectables (LAIs) such as crystalline suspensions and polymer-based implants by considering their distinct characteristics. The goal of the project is to develop a bottom-up mechanistic PBPK model for these two LAI categories by accounting for the influence of critical formulation attributes of each LAI drug product type to predict its in vivo release mechanism. The model formulation parameters and relevant physiology should be informed with suitable in vitro and in vivo experiments. A suitable preclinical animal model can be used to validate the PBPK model based IVIVCs for both LAI suspensions |
| Agency contact | Terrin.Brown@fda.hhs.gov |
| Official listing | https://www.grants.gov/search-results-detail/351078 |